结核分枝杆菌二线药物耐药突变与患者死亡率升高相关
该多国观察性队列研究分析了451例耐多药/广泛耐药结核病患者的临床、微生物学及测序数据,探讨结核分枝杆菌耐药突变与患者死亡率的关系。结果显示,rrs 1401G突变及高水平氟喹诺酮和卡那霉素耐药相关突变与患者死亡率升高显著相关。这些发现对分子诊断结果的解读及识别治疗期间高风险死亡患者具有重要意义。
要点
- rrs 1401G突变与患者死亡率升高显著相关(校正OR=5.72)。
- 高水平氟喹诺酮耐药突变与死亡率升高相关(OR=3.99)。
- 高水平卡那霉素耐药突变与死亡率升高相关(OR=5.47)。
核心结论
- 特定rrs和gyrA耐药突变与耐多药/广泛耐药结核病患者死亡率升高显著相关。
研究设计与样本
- 多国观察性队列研究,纳入451例患者及其临床分离株,分析临床、微生物学和测序数据。
主要发现
- rrs 1401G突变与患者死亡率升高相关(校正OR=5.72;95%CI 1.65-19.84)。
- 高水平氟喹诺酮耐药突变与死亡率升高相关(OR=3.99;95%CI 1.10-14.40)。
- 高水平卡那霉素耐药突变与死亡率升高相关(OR=5.47;95%CI 1.64-18.24)。
临床怎么用
- 分子诊断检测到rrs 1401G或高水平氟喹诺酮/卡那霉素耐药突变时,可识别治疗期间死亡高风险患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid molecular diagnostics have great potential to limit the spread of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) (M/XDR-TB). These technologies detect mutations in the Mycobacterium tuberculosis genome that confer phenotypic drug resistance. However, there have been few data published regarding the relationships between the detected M. tuberculosis resistance mutations and M/XDR-TB treatment outcomes, limiting our current ability to exploit the full potential of molecular diagnostics. We analyzed clinical, microbiological, and sequencing data for 451 patients and their clinical isolates collected in a multinational, observational cohort study to determine if there was an association between M. tuberculosis resistance mutations and patient mortality. The presence of an rrs 1401G mutation was associated with significantly higher odds of patient mortality (adjusted odds ratio [OR] = 5.72; 95% confidence interval [CI], 1.65 to 19.84]) after adjusting for relevant patient clinical characteristics and all other resistance mutations. Further analysis of mutations, categorized by the associated resistance level, indicated that the detection of mutations associated with high-level fluoroquinolone (OR, 3.99 [95% CI, 1.10 to 14.40]) and kanamycin (OR, 5.47 [95% CI, 1.64 to 18.24]) resistance was also significantly associated with higher odds of patient mortality, even after accounting for clinical site, patient age, reported smoking history, body mass index (BMI), diabetes, HIV, and all other resistance mutations. Specific gyrA and rrs resistance mutations, associated with high-level resistance, were associated with patient mortality as identified in clinical M. tuberculosis isolates from a diverse M/XDR-TB patient population at three high-burden clinical sites. These results have important implications for the interpretation of molecular diagnostics, including identifying patients at increased risk for mortality during treatment. (This study has been registered at ClinicalTrials.gov under registration no. NCT02170441.).
引用
- Georghiou SB, Seifert M, Catanzaro DG, et al. Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs. J Clin Microbiol. 2017. PMID: 28404672. doi:10.1128/JCM.00152-17
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。